Neurocrine Biosciences (NASDAQ: NBIX) and Proteon Therapeutics (NASDAQ:PRTO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
This table compares Neurocrine Biosciences and Proteon Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation and Earnings
This table compares Neurocrine Biosciences and Proteon Therapeutics’ revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Proteon Therapeutics has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Neurocrine Biosciences and Proteon Therapeutics, as reported by MarketBeat.
||Strong Buy Ratings
Neurocrine Biosciences presently has a consensus price target of $102.77, indicating a potential upside of 4.61%. Proteon Therapeutics has a consensus price target of $3.00, indicating a potential upside of 22.45%. Given Proteon Therapeutics’ higher probable upside, analysts clearly believe Proteon Therapeutics is more favorable than Neurocrine Biosciences.
Volatility & Risk
Neurocrine Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
Institutional and Insider Ownership
50.6% of Proteon Therapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Proteon Therapeutics beats Neurocrine Biosciences on 7 of the 13 factors compared between the two stocks.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.